Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Capri Holdings Ltd (CPRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Capri Holdings Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Capri Holdings Ltd trades at $18.04 (market cap $2.07B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 19.3× Capri Holdings Ltd's market cap. Which is the better fit depends on your goals.
| ALNY | CPRI | |
|---|---|---|
Market Cap | $39.89B | $2.07B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $27.66 |
52-Week Low | $278.09 | $16.79 |
Enterprise Value | $38.15B | $3.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CPRI trades at $18.04, down 0.22% with bearish technical signals. The company reported mixed Q4 2026 results with an EPS beat but revenue challenges, while showing a net loss of $1.18 billion in 2025. Analyst consensus is divided with a $23.33 price target, and recent news highlights a post-Versace turnaround focus on Michael Kors and Jimmy Choo brands.
The outlook hinges on successful execution of brand revamps and cost controls. Key risks include luxury demand volatility and high debt, but current valuation metrics like P/S of 0.62 may offer value if the turnaround gains traction. Institutional sentiment is cautiously optimistic with 44% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →
